Sai Life Sciences (NSE:SAILIFE) filed the transcript of its Q1 FY27 earnings conference call with the NSE on 12 August 2026. The call, held on 7 August 2026, disclosed total revenue of INR 553 crores for the quarter ended 30 June 2026, a 12% year-on-year increase from INR 496 crores in Q1 FY26.
Key Highlights
- Total revenue for Q1 FY27 reached INR 553 crores, up approximately 12% year-on-year from INR 496 crores in Q1 FY26.
- The CRO business grew 26% year-on-year and contributed approximately 40% of total Q1 FY27 revenues, with CDMO contributing the remaining 60%.
- Management stated that a stronger second half is anticipated, supported by planned capacity expansion going live in H2 FY27.
- A greenfield peptide manufacturing facility near Hyderabad has been announced, with an expected operational date in 2028, according to the conference call transcript.
About the Company
Sai Life Sciences (NSE:SAILIFE), headquartered in Gachibowli, Hyderabad, Telangana, is a contract research, development and manufacturing organisation (CRDMO) serving global pharmaceutical and biotechnology clients. The company provides integrated small molecule services spanning discovery, development and commercial manufacturing, with operations across multiple facilities in Hyderabad. It was incorporated in 1999 under CIN L24110TG1999PLC030970.
Announcement in Detail
The transcript filed on 12 August 2026 covers the earnings conference call moderated by E&Y Investor Relations on 7 August 2026. Managing Director and CEO Krishna Kanumuri and CFO Siva Chittor represented management. Kanumuri noted that geopolitical uncertainty and intellectual property concerns are reinforcing India's role in global pharma outsourcing strategies, strengthening demand for the company's services.
CFO Siva Chittor confirmed total revenue of INR 553 crores for Q1 FY27, with CDMO revenues growing approximately 6% year-on-year and CRO revenues rising approximately 26% year-on-year. The company disclosed plans to open an XDC Center of Excellence covering payloads, linkers, and conjugation, and stated that a formulation capability is expected to be operationally ready within approximately six months from the call date.
Impact on Investors
The filing shows that revenue growth of 12% year-on-year was driven primarily by the CRO segment, while CDMO growth remained more modest at approximately 6%. Investors will note that management attributed the comparatively lower CDMO growth to timing, with capacity expansion scheduled for H2 FY27 expected to support higher utilisation in the second half of the financial year.
Shareholders will observe that the company is committing capital to new modalities, including peptides, XDC, and formulation, and to a greenfield manufacturing site, which implies ongoing capital expenditure in the near to medium term. The disclosed terms of these expansion commitments carry execution and timeline risk that investors may wish to consider alongside the company's stated balance sheet flexibility.
Sector / Market Context
India's pharmaceutical contract manufacturing and research sector has seen increasing interest from global innovator companies seeking to reduce dependence on single geographies. According to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), India's pharma exports have consistently grown over recent years, with CRDMO services forming a growing share. India's established chemistry talent pool and regulatory-compliant manufacturing infrastructure continue to position the country as a preferred outsourcing destination for both large pharmaceutical companies and emerging biotechs, trends that are consistent with the customer engagement commentary provided by Sai Life Sciences management in the Q1 FY27 call.